Related Experiment Video
Updated: May 22, 2026
Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects
Weili Gao1, Ketao Jin, Huanrong Lan
1Department of General Surgery, Huzhou Central Hospital, Huzhou, Zhejiang, China.
Background/Aims:
Vascular endothelial growth fac-tor (VEGF) serves as a logical target for antiangiogenic cancer therapy. This study is to investigate the inhibitory effects of FP3, a novel VEGF blocker, on angiogenesis in vitro and in vivo as well as anti-tumor effects ona liver cancer xenograft model in vivo.
Methodology:
The inhibitory effects of FP3 on angiogenesis were assessed by using human umbilical vein endothelial cells(HUVECs) in vitro and the chick embryo chorioallantoialc membrane (CAM) in viva. The inhibitory effect of FP3 on tumor growth in viva were evaluated in a human liver cancer cell line Hep-3B xenograft model in nude mice with the methods of tumor growth regression as-say.
Results:
In experiments with HUVECs, FP3 inhibit-ed cell survival and tube formation. In CAM assay, FP3 suppressed MCF-7 human breast cancer cell-induced angiogenesis. In tumor growth regression assay, FP3 significantly blocked the growth of Hep-3B tumor cellin subcutaneous tumor xenograft model in nude mice.
Conclusions:
FP3 has excellent inhibitory effects on angiogenesis both in vitro and in viva and antitumor effect on liver cancer xenograft model; therefore, it might be used as an effective antiangiogenic agent in treatment of liver cancer.
Insights
FP3, a novel vascular endothelial growth factor (VEGF) blocker, effectively inhibits angiogenesis in vitro and in vivo. This agent also demonstrates significant anti-tumor effects in a liver cancer model, suggesting its therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Vascular endothelial growth factor (VEGF) is a key target for antiangiogenic cancer therapies.
- FP3 is a novel compound designed to block VEGF activity.
- Targeting angiogenesis is a promising strategy for cancer treatment.
Purpose of the Study:
- To investigate the anti-angiogenic effects of FP3 in vitro and in vivo.
- To evaluate the anti-tumor efficacy of FP3 in a liver cancer xenograft model.
Main Methods:
- In vitro: Human umbilical vein endothelial cell (HUVEC) assays for cell survival and tube formation.
- In vivo (angiogenesis): Chick embryo chorioallantoic membrane (CAM) assay using MCF-7 breast cancer cells.
- In vivo (tumor growth): Hep-3B liver cancer cell xenograft model in nude mice, assessing tumor growth regression.
Main Results:
- FP3 inhibited HUVEC cell survival and tube formation in vitro.
- FP3 suppressed angiogenesis induced by MCF-7 cells in the CAM assay.
- FP3 significantly inhibited the growth of Hep-3B tumors in a mouse xenograft model.
Conclusions:
- FP3 exhibits potent inhibitory effects on angiogenesis both in vitro and in vivo.
- FP3 demonstrates significant anti-tumor activity in a liver cancer xenograft model.
- FP3 holds promise as an effective anti-angiogenic agent for liver cancer treatment.
More Related Videos
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:24Regulation of Angiogenesis and Blood Supply
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:10Mechanism of Angiogenesis